The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

FDA的这一批准是对HER2低表达和超低表达乳腺癌患者未来治疗选择的良好补充，显示了新型靶向疗法在癌症治疗中的巨大潜力。期待在未来的研究中，Enhertu能为更多患者带来生机与希望。 返回搜狐，查看更多 ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

▎药明康德内容团队编辑今日，第一三共（Daiichi Sankyo）与阿斯利康（AstraZeneca）共同宣布，其联合开发的重磅抗体偶联药物（ADC）Enhertu（trastuzumab ...

Roche is the recipient of the new approval, getting the go-ahead from the US regulator for its PATHWAY HER2 (4B5) test to ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

The government had earlier cut customs duties on Trastuzumab Deruxtecan, Osimertinib and Durvalumab from 10 per cent to nil ...

Finance Minister Nirmala Sitharaman presented the Union Budget 2025, highlighting measures to enhance healthcare ...